BioDelivery Sciences International, Inc. (BDSI) Director Francis E. Odonnell, Jr. Sells 8,000 Shares

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Director Francis E. Odonnell, Jr. sold 8,000 shares of the stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $5.19, for a total transaction of $41,520.00. Following the transaction, the director now owns 606,254 shares in the company, valued at $3,146,458.26. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

BDSI stock opened at $4.84 on Friday. BioDelivery Sciences International, Inc. has a twelve month low of $1.70 and a twelve month high of $5.37. The company has a debt-to-equity ratio of 1.74, a current ratio of 3.07 and a quick ratio of 2.82. The company has a market cap of $342.69 million, a PE ratio of -6.63 and a beta of 0.46.

BioDelivery Sciences International (NASDAQ:BDSI) last released its quarterly earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.10) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.10). BioDelivery Sciences International had a negative net margin of 60.87% and a negative return on equity of 79.59%. The business had revenue of $18.03 million during the quarter, compared to the consensus estimate of $16.15 million. On average, analysts anticipate that BioDelivery Sciences International, Inc. will post -0.24 EPS for the current year.

Several hedge funds have recently added to or reduced their stakes in the company. Stonepine Capital Management LLC grew its position in shares of BioDelivery Sciences International by 190.1% during the third quarter. Stonepine Capital Management LLC now owns 4,311,103 shares of the specialty pharmaceutical company’s stock worth $12,071,000 after buying an additional 2,825,101 shares in the last quarter. Nantahala Capital Management LLC lifted its stake in BioDelivery Sciences International by 64.0% during the fourth quarter. Nantahala Capital Management LLC now owns 2,733,567 shares of the specialty pharmaceutical company’s stock worth $10,114,000 after purchasing an additional 1,066,900 shares during the last quarter. Vanguard Group Inc lifted its stake in BioDelivery Sciences International by 0.3% during the third quarter. Vanguard Group Inc now owns 2,380,456 shares of the specialty pharmaceutical company’s stock worth $6,666,000 after purchasing an additional 7,600 shares during the last quarter. Point72 Asset Management L.P. lifted its stake in BioDelivery Sciences International by 150.0% during the third quarter. Point72 Asset Management L.P. now owns 1,500,000 shares of the specialty pharmaceutical company’s stock worth $4,200,000 after purchasing an additional 900,000 shares during the last quarter. Finally, BlackRock Inc. lifted its stake in BioDelivery Sciences International by 15.8% during the fourth quarter. BlackRock Inc. now owns 1,388,297 shares of the specialty pharmaceutical company’s stock worth $5,137,000 after purchasing an additional 189,508 shares during the last quarter. 57.17% of the stock is owned by institutional investors and hedge funds.

Several research analysts recently commented on BDSI shares. Janney Montgomery Scott restated a “buy” rating and issued a $5.00 price target on shares of BioDelivery Sciences International in a report on Thursday, January 31st. Zacks Investment Research downgraded shares of BioDelivery Sciences International from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 11th. Cantor Fitzgerald set a $5.00 price objective on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research report on Friday, January 25th. BidaskClub raised shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research report on Friday, January 11th. Finally, SunTrust Banks began coverage on shares of BioDelivery Sciences International in a research report on Tuesday, March 19th. They issued a “buy” rating and a $7.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. BioDelivery Sciences International has a consensus rating of “Buy” and an average price target of $5.79.

ILLEGAL ACTIVITY WARNING: “BioDelivery Sciences International, Inc. (BDSI) Director Francis E. Odonnell, Jr. Sells 8,000 Shares” was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.baseballdailydigest.com/news/2019/04/26/biodelivery-sciences-international-inc-bdsi-director-francis-e-odonnell-jr-sells-8000-shares.html.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Read More: What is a Real Estate Investment Trust (REIT)?

Insider Buying and Selling by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.